The US Food and Drug Administration (FDA) recently held a landmark advisory panel meeting regarding the Galleri test, developed by the company Grail. The panel voted in favor of the technology, which aims to identify various forms of cancer through a single blood draw. This endorsement represents a major step forward for the field of multi-cancer early detection (MCED), as it is the first time US regulators have signaled support for such a diagnostic tool.

Despite the positive reception from US regulators, the medical community remains divided on the practical application of these tests. In Hong Kong, doctors have voiced caution, questioning whether the current clinical evidence is sufficient to justify widespread use. Critics and medical experts in these regions emphasize that while the technology is innovative, it must be rigorously vetted to ensure it provides genuine clinical value rather than simply generating false positives or unnecessary anxiety for patients. The discrepancy between the US regulatory endorsement and the international medical community's hesitation highlights the ongoing debate over how to balance rapid innovation in biotechnology with established standards for diagnostic accuracy.